These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 32216566)

  • 21. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma.
    Guevara IL; Pandya AG
    Int J Dermatol; 2003 Dec; 42(12):966-72. PubMed ID: 14636195
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The role of 755-nm alexandrite picosecond laser in melasma management.
    Pulumati A; Jaalouk D; Algarin YA; Nouri K
    Arch Dermatol Res; 2023 Dec; 316(1):60. PubMed ID: 38151661
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A comparative study on efficacy of high and low fluence Q-switched Nd:YAG laser and glycolic acid peel in melasma.
    Kar HK; Gupta L; Chauhan A
    Indian J Dermatol Venereol Leprol; 2012; 78(2):165-71. PubMed ID: 22421647
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A pilot study for triple combination therapy with a low-fluence 1064 nm Q-switched Nd:YAG laser, hydroquinone cream and oral tranexamic acid for recalcitrant Riehl's Melanosis.
    Kwon HH; Ohn J; Suh DH; Park HY; Choi SC; Jung JY; Kwon IH; Park GH
    J Dermatolog Treat; 2017 Mar; 28(2):155-159. PubMed ID: 27346606
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Fractional erbium:YAG laser (2940 nm) plus topical hydroquinone compared to intradermal tranexamic acid plus topical hydroquinone for the treatment of refractory melasma: a randomized controlled trial.
    Mokhtari F; Bahrami B; Faghihi G; Asilian A; Iraji F
    J Dermatolog Treat; 2022 Aug; 33(5):2475-2481. PubMed ID: 34387527
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 755-nm picosecond laser plus topical 20% azelaic acid compared to topical 20% azelaic acid alone for the treatment of melasma: a randomized, split-face and controlled trial.
    Lai D; Cheng S; Zhou S; Hao J; Chen H; Jia K; Liu H; Cui Y
    Lasers Med Sci; 2024 Apr; 39(1):113. PubMed ID: 38656631
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of the 1064-nm Q-switched Nd:YAG laser in melasma.
    Suh KS; Sung JY; Roh HJ; Jeon YS; Kim YC; Kim ST
    J Dermatolog Treat; 2011 Aug; 22(4):233-8. PubMed ID: 20443754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized, split-face clinical trial of low-fluence Q-switched neodymium-doped yttrium aluminum garnet (1,064 nm) laser versus low-fluence Q-switched alexandrite laser (755 nm) for the treatment of facial melasma.
    Fabi SG; Friedmann DP; Niwa Massaki AB; Goldman MP
    Lasers Surg Med; 2014 Sep; 46(7):531-7. PubMed ID: 24895301
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Retrospective analysis of the treatment of melasma lesions exhibiting increased vascularity with the 595-nm pulsed dye laser combined with the 1927-nm fractional low-powered diode laser.
    Geddes ER; Stout AB; Friedman PM
    Lasers Surg Med; 2017 Jan; 49(1):20-26. PubMed ID: 28134994
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-fluence Q-switched Nd: YAG 1064-nm laser and intense pulsed light for the treatment of melasma.
    Vachiramon V; Sirithanabadeekul P; Sahawatwong S
    J Eur Acad Dermatol Venereol; 2015 Jul; 29(7):1339-46. PubMed ID: 25413592
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety Evaluation of Picosecond Alexandrite Laser with a Diffractive Lens Array for Treatment of Melasma in Asian Patients by VISIA Imaging System.
    Chen YT; Lin ET; Chang CC; Lin BS; Chiang HM; Huang YH; Lin HY; Wang KY; Chang TM
    Photobiomodul Photomed Laser Surg; 2019 Sep; 37(9):559-566. PubMed ID: 31411549
    [No Abstract]   [Full Text] [Related]  

  • 32. A split-face comparison of fractional erbium: YAG laser plus Kligman's formula vs. Kligman's formula monotherapy for facial melasma.
    Nasimi M; Ghiasi M; Lajevardi V; Nasiri F; Shakoei S
    Arch Dermatol Res; 2022 Oct; 314(8):791-797. PubMed ID: 34705101
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postinflammatory and rebound hyperpigmentation as a complication after treatment efficacy of telangiectatic melasma with 585 nanometers Q-switched Nd: YAG laser and 4% hydroquinone cream in skin phototypes III-V.
    Lueangarun S; Namboonlue C; Tempark T
    J Cosmet Dermatol; 2021 Jun; 20(6):1700-1708. PubMed ID: 33002283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-fluence Q-switched neodymium-doped yttrium aluminum garnet laser for melasma with pre- or post-treatment triple combination cream.
    Jeong SY; Shin JB; Yeo UC; Kim WS; Kim IH
    Dermatol Surg; 2010 Jun; 36(6):909-18. PubMed ID: 20384749
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparative study of therapeutic effects of 20% azelaic acid and hydroquinone 4% cream in the treatment of melasma.
    Farshi S
    J Cosmet Dermatol; 2011 Dec; 10(4):282-7. PubMed ID: 22151936
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A Prospective, Split-Face, Randomized Study Comparing a 755-nm Picosecond Laser With and Without Diffractive Lens Array in the Treatment of Melasma in Asians.
    Manuskiatti W; Yan C; Tantrapornpong P; Cembrano KAG; Techapichetvanich T; Wanitphakdeedecha R
    Lasers Surg Med; 2021 Jan; 53(1):95-103. PubMed ID: 32865858
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A comparative study of low-fluence 1064-nm Q-switched Nd:YAG laser with or without chemical peeling using Jessner's solution in melasma patients.
    Lee DB; Suh HS; Choi YS
    J Dermatolog Treat; 2014 Dec; 25(6):523-8. PubMed ID: 24289244
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term results in low-fluence 1064-nm Q-Switched Nd:YAG laser for melasma: Is it effective?
    Gokalp H; Akkaya AD; Oram Y
    J Cosmet Dermatol; 2016 Dec; 15(4):420-426. PubMed ID: 27349828
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluating the tolerance and efficacy of laser-assisted delivery of tranexamic acid, niacinamide, and kojic acid for melasma: A single center, prospective, split-face trial.
    Park SJ; Park JW; Seo SJ; Park KY
    Dermatol Ther; 2022 Mar; 35(3):e15287. PubMed ID: 34962047
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessment of combined fractional CO
    Tawfic SO; Abdel Halim DM; Albarbary A; Abdelhady M
    Lasers Surg Med; 2019 Jan; 51(1):27-33. PubMed ID: 30431171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.